Clinical study of adrenal imaging with 123I-labeled-6 beta-iodomethyl-19-norcholesterol (author's transl)

F. Shishido, Y. Tateno, T. Ido, T. Irie, K. Suzuki, K. Fukushi, R. Iwata, M. Kojima, M. Maeda, T. Ito, H. Ogawa

Research output: Contribution to journalArticlepeer-review


Although adrenal scintigraphy with 131I-6 beta-iodomethyl-19-norcholesterol (NCL-6-131I) was used for the first noninvasive imaging of the adrenal glands, it has the disadvantages. These are: (i) relatively high radiation dose to patients, (ii) the long time required for completion of the scan. To solve these problems, 123I-labeled 6 beta-iodomethyl-19-norcholesterol (NCL-6-123I) was synthesized and was used for adrenal scintigraphy in 6 cases. Successful images were obtained with 185 MBq (5 mCi)-260 MBq (7 mCi) of NCL-6-123I, and optimal time required for the satisfactory scan was 2-3 days after the administration. The estimate radiation dose was reduced by using 185 MBq (5 mCi) of NCL-6-123I instead of 18.5 MBq (0.5 mCi) of NCL-6-131I. From the result of this clinical study, NCL-6-123I was preferred for the adrenal scintigraphy.

Original languageEnglish
Pages (from-to)526-532
Number of pages7
Issue number11
Publication statusPublished - 1980 Nov
Externally publishedYes

ASJC Scopus subject areas

  • Radiation


Dive into the research topics of 'Clinical study of adrenal imaging with 123I-labeled-6 beta-iodomethyl-19-norcholesterol (author's transl)'. Together they form a unique fingerprint.

Cite this